- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/04 - AnorexiantsAntiobesity agents
Patent holdings for IPC class A61P 3/04
Total number of patents in this class: 7591
10-year publication summary
|
227
|
338
|
441
|
445
|
565
|
542
|
527
|
572
|
665
|
557
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novo Nordisk A/S | 2284 |
84 |
| Takeda Pharmaceutical Company Limited | 2713 |
80 |
| Eli Lilly and Company | 4106 |
80 |
| Shionogi & Co., Ltd. | 884 |
69 |
| Boehringer Ingelheim International GmbH | 4487 |
59 |
| Pfizer Inc. | 3400 |
54 |
| LG Chem, Ltd. | 17937 |
49 |
| Société des Produits Nestlé S.A. | 10039 |
48 |
| Daiichi Sankyo Company, Limited | 1890 |
43 |
| Nestec S.A. | 2552 |
41 |
| Janssen Pharmaceutica N.V. | 3160 |
41 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 874 |
40 |
| Taisho Pharmaceutical Co., Ltd. | 851 |
40 |
| The Regents of the University of California | 20790 |
39 |
| Novartis AG | 10224 |
38 |
| Sunshine Lake Pharma Co., Ltd. | 627 |
38 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3256 |
32 |
| Amgen Inc. | 4431 |
31 |
| Ajinomoto Co., Inc. | 2279 |
30 |
| Regeneron Pharmaceuticals, Inc. | 4741 |
30 |
| Other owners | 6625 |